ARA-C


Also found in: Medical.
AcronymDefinition
ARA-C1-Beta-D-Arabinofuranosylcytosine
ARA-CArabinoside C
References in periodicals archive ?
Evaluation of the Amount of Ara-C Immobilized to BMs.
The tests of Ara-C released from various samples were performed by placing the sample containing tubes in an incubator shaker at 60 rpm, 37[degrees]C with magnet absorption.
The changes indicate that Ara-C is successfully loaded onto the BMs.
The FTIR spectra of Ara-C, ABMs-GP, ABMs-G, ABMs, and BMs samples are shown in Figure 2.
To summarize, we suggest that the wide spectrum of clinical presentation associated with ARA-C might have a common underlying mechanism, which triggers the cytokine network.
Subacute pulmonary failure complicating therapy with high dose ARA-C in acute leukemia.
Ara-C has no effect on Escherichia coli, since the bacteria lack dCK that phosphorylates Ara-C into its active form and they actively deaminate Ara-C into Ara-uracil through the activity of cytidine/deoxycytidine deaminase (cdd).
coli MG1655 strain with enhanced sensitivity toward Ara-C in rich medium and its use as a bioluminescent biosensor in an 8-h assay to determine Ara-C uptake as well as its phosphorylation by human leukemic cells.
Cryopreserved bone marrow samples, previously separated by density gradient centrifugation to yield the mononuclear cell fraction, were thawed and resuspended in RPMI 1640 medium before incubation with Ara-C. Mononuclear cells from fresh AML peripheral blood samples (collected from patients at Frimley Park Hospital, Surrey, UK, and Bristol Haematology and Oncology Centre, Bristol, UK, after obtaining informed consent) were also isolated by density gradient centrifugation and resuspended in RPMI 1640 medium.
Samples of 200 [micro]L with either Ara-C or fludarabine (F-ara-A) concentrations of 0-100 [micro]mol/L and 1 mmol/L IPTG were loaded into a black-walled microtiter plate (Invitrogen).
In a Phase 1 study, amonafide and ara-C in patients with poor-risk AML demonstrated a clinical response rate of 46% (12/26), with 38% (10/26) achieving complete remission and two patients achieving near-complete remission.
Although researchers still do not know how it works, EGF "may prove useful" as a topical preventive for hair loss among cancer patients receiving ARA-C, Yunis says.